Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.381679389 Mexican pesos per share on its common stock representing a total amount of $ 400,000,000.00 M.N. (four hundred million pesos 00/100 National Currency), payable to shareholders of record at the close of business on November 11, 2022. This amount is based on the total LABB shares currently in circulation. This payment is in addition to the dividends paid previously on December 10, 2021 and on June 08, 2022.
The Company has reported that all lines in the Personal Care Manufacturing Plant are currently in operation and are in the ramp up process. No significant additional Capex will be required.
Genomma’s Board of Directors, exercising the powers delegated at the last Annual General Shareholders Meeting, have therefore deemed it appropriate to make today’s announced third payment, also signaling the next phase of shareholder value generation. Genomma Lab and its Board of Directors express their continued appreciation for the trust of its shareholders and financial providers, including the International Finance Corporation (IFC) and the Inter-American Development Bank (IDB).
It’s important to note that the above dividend payment is derived from the Net Tax Profit Account (CUFIN) prior to 2014.
